Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 4/20 | 0.63 |
| ▸ | CCNE1 | P24864 | 3/20 | 0.63 |
| ▸ | CDK5 | Q00535 | 3/20 | 0.63 |
| ▸ | RAB9A | P51151 | 4/20 | 0.62 |
| ▸ | NPC1 | O15118 | 3/20 | 0.62 |
| ▸ | MEN1 | O00255 | 3/20 | 0.62 |
| ▸ | MAPT | P10636 | 3/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.62 |
| ▸ | HTT | P42858 | 2/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.62 |
| ▸ | LMNA | P02545 | 1/20 | 0.62 |
| ▸ | CNR1 | P21554 | 1/20 | 0.56 |
| ▸ | FBP1 | P09467 | 4/20 | 0.55 |
| ▸ | AURKA | O14965 | 1/20 | 0.55 |
| ▸ | PIM1 | P11309 | 1/20 | 0.55 |
| ▸ | GSK3B | P49841 | 1/20 | 0.55 |
| ▸ | TP53 | P04637 | 1/20 | 0.53 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6285988 | 0.86 | MDM2 (0.58) | CDK2CCNE1CDK5RAB9ANPC1 | |
| SCHEMBL6287994 | 0.86 | SMN1; SMN2 (0.52) | CDK2CCNE1CDK5RAB9ANPC1 | |
| SCHEMBL6279150 | 0.85 | TSHR (0.55) | CDK2CCNE1CDK5RAB9ANPC1 | |
| SCHEMBL6283549 | 0.85 | MAPT (0.56) | CDK2CCNE1CDK5RAB9ANPC1 | |
| SCHEMBL6285641 | 0.85 | RAB9A (0.70) | RAB9ANPC1MEN1MAPTKMT2A | |
| SCHEMBL6285669 | 0.84 | DYRK1A (0.56) | CDK2CCNE1CDK5RAB9ANPC1 | |
| SCHEMBL6285829 | 0.83 | FBP1 (0.65) | CDK2CCNE1CDK5RAB9ANPC1 | |
| SCHEMBL6287753 | 0.83 | FBP1 (0.65) | RAB9ANPC1MEN1MAPTKMT2A | |
| SCHEMBL6278432 | 0.81 | SMN1; SMN2 (0.60) | RAB9ANPC1MEN1MAPTKMT2A | |
| SCHEMBL6285776 | 0.81 | RAB9A (0.74) | CDK2CCNE1CDK5RAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040157827-A1 | 2-Ureido-thiazole derivatives, process for their preparation, and their use as antitumor agents | PEVARELLO PAOLO (IT) | 2004-08-12 | — | — | US | claimed |
| US-20030187040-A1 | 2-Ureido-thiazole derivatives, process for their preparation, and their use as antitumor agents | PHARMACIA & UPJOHN SPA (IT) | 2003-10-02 | — | — | US | claimed |
| EP-1737463-B1 | PYRIMIDINES WITH TIE2 (TEK) ACTIVITY | ASTRAZENECA AB (SE) | 2008-12-03 | — | — | EP | disclosed |
| CN-101273023-A | 5-substituted thiazol-2-ylamino compounds and compositions as protein kinase inhibitors | IRM LLC (BM) | 2008-09-24 | — | — | CN | disclosed |
| US-20080227783-A1 | 5-Substituted Thiazol-2-Yl Amino Compounds and Compositions as Protein Kinase Inhibitors | IRM LLC (BM) | 2008-09-18 | — | — | US | disclosed |
| US-20080227783-A1 | 5-Substituted Thiazol-2-Yl Amino Compounds and Compositions as Protein Kinase Inhibitors | IRM LLC (BM) | 2008-09-18 | — | — | US | disclosed |
| US-20080227783-A1 | 5-Substituted Thiazol-2-Yl Amino Compounds and Compositions as Protein Kinase Inhibitors | IRM LLC (BM) | 2008-09-18 | — | — | US | disclosed |
| US-20080108608-A1 | Pyrimidines With Tie2 (Tek) Activity | ASTRAZENECA AB (SE) | 2008-05-08 | — | — | US | disclosed |
| WO-2007016228-A2 | 5-SUBSTITUTED THIAZOL-2-YL AMINO COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2007-02-08 | — | — | WO | disclosed |
| EP-1737463-A1 | PYRIMIDINES WITH TIE2 (TEK) ACTIVITY | AstraZeneca AB (SE) | 2007-01-03 | — | — | EP | disclosed |
| WO-2005060970-A1 | PYRIMIDINES WITH TIE2 (TEK) ACTIVITY | ASTRAZENECA AB (SE) | 2005-07-07 | — | — | WO | disclosed |
| US-6863647-B2 | 2-Ureido-thiazole derivatives, process for their preparation, and their use as antitumor agents | PHARMACIA & UPJOHN S.P.A. (IT) | 2005-03-08 | — | — | US | disclosed |
| US-20040157827-A1 | 2-Ureido-thiazole derivatives, process for their preparation, and their use as antitumor agents | PEVARELLO PAOLO (IT) | 2004-08-12 | — | — | US | disclosed |
| US-20030187040-A1 | 2-Ureido-thiazole derivatives, process for their preparation, and their use as antitumor agents | PHARMACIA & UPJOHN SPA (IT) | 2003-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080108608-A1 | Pyrimidines With Tie2 (Tek) Activity | TIE1, TEK, TEKT1 | CDK2 62/4885CCNE1 361/4885CDK5 988/4885 |
| US-20080227783-A1 | 5-Substituted Thiazol-2-Yl Amino Compounds and Compositions as Protein Kinase Inhibitors | BMX, CDK1, CKS1B | CDK2 13/4885CCNE1 282/4885CDK5 46/4885 |
| US-20030187040-A1 | 2-Ureido-thiazole derivatives, process for their preparation, and their use as antitumor agents | UCK2, ULK3, CDK2 | CDK2 3/4885CCNE1 83/4885CDK5 129/4885 |
| US-20040157827-A1 | 2-Ureido-thiazole derivatives, process for their preparation, and their use as antitumor agents | UCK2, ULK3, CDK2 | CDK2 3/4885CCNE1 83/4885CDK5 129/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.